Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | Investigating p-tau217 as a clinical screening tool

Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, discusses her study investigating plasma p-tau217 as a clinical trial screening tool. Dr Lukasewicz Ferreria is currently exploring thresholds for positivity since none are established yet, aiming to streamline participant selection. Testing liberal, intermediate, and conservative thresholds, they found the intermediate threshold of balanced sensitivity and specificity to be most effective for trial inclusion. This approach reduces the necessary sample size, amyloid-PET scan requirements, and recruitment costs. While plasma p-tau217 may help in initial screenings, amyloid-PET remains crucial for confirming brain pathology. Both tools have advantages, with plasma p-tau217 useful for efficient participant recruitment, while PET scans provide detailed pathology distribution information. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.